84 completed, 19 terminated, 17 recruiting, 12 active not recruiting. 147 Phase 1, 27 Phase 2.
Follow Medulloblastoma: new trials by email Literature Review of Medulloblastoma trials Research Report on Medulloblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma administration of axitinib in combination with etoposide - Medulloblastoma, Ependymoma | Phase 1 / Phase 2 | Recruiting | Assistance Publique Hopitaux De Marseille | 40 | 2032-02-01 | 2026-11-12 |
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-11-30 | 2026-10-30 |
| B7-H3.CD28Z.CART in CNS Neoplasms B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Central Nervous System Neoplasms, Brain Tumor | Phase 1 | Recruiting | Robbie Majzner | 70 | 2026-09-01 | 2026-09-03 |
| Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma RVU120, Everolimus (Afinitor) tablets - Medulloblastoma Recurrent, Medulloblastoma | Phase 1 | Not yet recruiting | Bożenna Dembowska Bagińska | 48 | 2026-09-01 | 2026-10-08 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) 25 mCi 177Lu- DTPA-omburtamab - Recurrent Medulloblastoma, Refractory Medulloblastoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-07-02 | 2026-10-08 |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Becotatug Vedotin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma | Phase 1 | Recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-13 |
| RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) - Recurrent Medulloblastoma | Phase 1 | Recruiting | University of Florida | 24 | 2026-04-24 | 2026-11-16 |
| GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults GPC2-CAR T cells, Fludarabine, Cyclophosphamide - Medulloblastoma, Central Nervous System Embryonal Tumor | Phase 1 | Recruiting | Stanford University | 18 | 2025-08-28 | 2026-10-09 |
| Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine - Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma | Phase 1 | Recruiting | University of Florida | 12 | 2025-05-05 | 2026-11-02 |
| Atovaquone Combined With Radiation in Children With Malignant Brain Tumors Atovaquone, Radiation Therapy - High-grade Glioma, Medulloblastoma | Phase 1 | Recruiting | Emory University | 18 | 2025-03-28 | 2026-08-03 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy - Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS | Phase 1 | Recruiting | Children's National Research Institute | 12 | 2024-09-20 | 2026-10-13 |
| Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies Nivolumab, Methotrexate, 5-Azacytidine - Recurrent Ependymoma, Recurrent Medulloblastoma | Phase 1 | Withdrawn | Jeffrey Treiber | 2024-07-15 | 2026-01-08 | |
| PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications PLX038 - Glioma, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 146 | 2024-01-31 | 2026-11-06 |
| GD2-CAR T Cells for Pediatric Brain Tumours GD2-CART01 (iC9-GD2-CAR T-cells) - Brain Tumor, Pediatric, Medulloblastoma, Childhood | Phase 1 | Recruiting | Bambino Gesù Hospital and Research Institute | 54 | 2023-11-09 | 2026-09-30 |
| Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors B7-H3-CAR T cells - Central Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Active not recruiting | St. Jude Children's Research Hospital | 29 | 2023-04-27 | 2026-07-06 |
| Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Topotecan, Temozolomide, Ribociclib - Neuroblastoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 12 | 2022-12-27 | 2025-10-10 |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-11-16 |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years - Medulloblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Children's Oncology Group | 35 | 2022-07-01 | 2026-06-02 |
Showing 20 of 147. Sign in to see all of them.
Astrocytoma (76) · Central Nervous System Neoplasms (58) · Oligodendroglioma (57) · Glioma (55) · Ependymoma (49) · Familial ependymoma (48) · Brain Neoplasms (46) · Choroid Plexus Neoplasms (43) · Glioblastoma (43) · Optic Nerve Glioma (42) · Neuroblastoma (40) · Neuroectodermal Tumors, Primitive (35) · Rhabdoid Tumor (33) · Pinealoma (28)
Neoplasms by Histologic Type (146) · Neoplasms, Glandular and Epithelial (146) · Neoplasms, Nerve Tissue (146) · Neuroectodermal Tumors (143) · Neoplasms, Neuroepithelial (141) · Neoplasms (137) · Neoplasms, Germ Cell and Embryonal (137) · Neoplasms by Site (114) · Neuroectodermal Tumors, Primitive (112) · Nervous System Diseases (106) · Nervous System Neoplasms (106) · Central Nervous System Diseases (96) · Brain Diseases (93) · Glioma (92) · Neoplasms, Complex and Mixed (49)
Temozolomide (21) · Filgrastim (14) · Carboplatin (11) · Cyclophosphamide (9) · Etoposide (8) · Granulocyte Colony-Stimulating Factor (7) · Irinotecan (6) · Melphalan (6) · Peripheral Blood Stem Cell Transplantation (6) · Radiotherapy (6) · Thiotepa (5) · Busulfan (4) · Magnetic Resonance Spectroscopy (4) · Vincristine (4) · Vorinostat (4)
National Cancer Institute (NCI) (28) · Pediatric Brain Tumor Consortium (13) · National Institutes of Health Clinical Center (CC) (6) · Novartis Pharmaceuticals (6) · Children's Oncology Group (5) · City of Hope Medical Center (5) · Duke University (4) · M.D. Anderson Cancer Center (4) · Emory University (3) · Masonic Cancer Center, University of Minnesota (3) · OHSU Knight Cancer Institute (3) · Seattle Children's Hospital (3) · St. Jude Children's Research Hospital (3) · Eli Lilly and Company (2) · Giselle Sholler (2)
United States (131) · Canada (13) · United Kingdom (8) · Australia (7) · Italy (7) · Spain (7) · France (6) · China (5) · Germany (5) · Switzerland (3) · Hong Kong (2) · Japan (2) · Netherlands (2) · Belgium (1) · Denmark (1)
Darell D. Bigner, MD, PhD (4) · Daniel Landi, MD (3) · Maryam Fouladi (3) · Amar Gajjar (2) · Edward A. Neuwelt, MD (2) · Elizabeth Fox, MD (2) · Giles W. Robinson, MD (2) · Giselle Sholler, MD (2) · James Croop, MD, PhD (2) · Jana Portnow, MD (2) · John P. Perentesis, MD (2) · Kim Kramer, MD (2) · Mark W. Kieran, MD, PhD (2)
PMID 11410496, PMID 15814645, PMID 16234526, PMID 16533779, PMID 16914576, PMID 17634493, PMID 17941066, PMID 18048828, PMID 18281544, PMID 18281546, PMID 18391430, PMID 18470481, PMID 19065567, PMID 19075272, PMID 19430790, PMID 20044751, PMID 20049936, PMID 20460632, PMID 20847174, PMID 21115653, PMID 21850464, PMID 23554030, PMID 27467121, PMID 28153957, PMID 29181270, PMID 31838007, PMID 31876107, PMID 33047248, PMID 34171339, PMID 34253928, PMID 35395680, PMID 35417530, PMID 35468680, PMID 36371226, PMID 37004712, PMID 37553297, PMID 37640679, PMID 37715730, PMID 38215438, PMID 39775044, PMID 40086048, PMID 41379553, PMID 41798119, PMID 9849694
U01CA081457 (14), U01CA097452 (8), UM1CA081457 (7), P30CA033572 (4), 2023 (2), 2008 (1), 2009 (1), 2019 (1), P30CA008748 (1), P30CA015083 (1), P30CA016087 (1), P30CA016672 (1), P30CA043703 (1), P30CA069533 (1), P30CA124435 (1)